<p>A. Females with ALS overlapped with female controls in the measured parameters. (t <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0113619#pone.0113619-Andersen1" target="_blank">[1]</a>, 34% of variation vs. t <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0113619#pone.0113619-Desport1" target="_blank">[2]</a>, 20% of variation; R2 = 0.67; Q2 = .25). B) The male ALS group was shifted from the male controls in the measured parameters. (t <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0113619#pone.0113619-Andersen1" target="_blank">[1]</a>, 36% of variation vs. t <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0113619#pone.0113619-Desport1" target="_...
<p>M: male; F: Female. B: bulbar onset; L: limb onset; MFO: interval from the observation of initial...
<p>Abbreviations: PMA = progressive muscular atrophy, ALS = amyotrophic lateral sclerosis, N = numbe...
<p>Box and dot plots show CSF NfH<sup>SMI35</sup> in ALS, Parkinson's disease (PD), and controls (CT...
<p>The first 3 principal components which account for most of the variance in the original data set ...
<p>Female subjects Average values ± standard deviation for parameters measured for female controls a...
We investigated whether the C9orf72 repeat expansion is associated with specific clinical features, ...
<p>Male subjects Average values ± standard deviation for parameters measured for male controls, ALS ...
<p><sup>a</sup>Fisher’s exact test refers to comparison between all ALS patients and healthy control...
International audienceBackground: Studies showed the impact of sex and onset site (spinal or bulbar)...
<p>N = Number of subjects, Ln = natural log transform. EES score: 1 = defined as possible ALS, 2 = p...
We investigated whether the C9orf72 repeat expansion is associated with specific clinical features, ...
<p>Principal Component Analysis score plot for ALS (n = 50) and non ALS patients (n = 44).</p
Replicable risk factors for ALS include increasing age, family history and being male. The male: fem...
<p>Leukocyte phenotypes from HVs and ALS patients sub-grouped into Profiles 1 and 2 were compared. <...
In the past decade, increasingly large-scale genome wide association studies (GWAS) have gleaned ins...
<p>M: male; F: Female. B: bulbar onset; L: limb onset; MFO: interval from the observation of initial...
<p>Abbreviations: PMA = progressive muscular atrophy, ALS = amyotrophic lateral sclerosis, N = numbe...
<p>Box and dot plots show CSF NfH<sup>SMI35</sup> in ALS, Parkinson's disease (PD), and controls (CT...
<p>The first 3 principal components which account for most of the variance in the original data set ...
<p>Female subjects Average values ± standard deviation for parameters measured for female controls a...
We investigated whether the C9orf72 repeat expansion is associated with specific clinical features, ...
<p>Male subjects Average values ± standard deviation for parameters measured for male controls, ALS ...
<p><sup>a</sup>Fisher’s exact test refers to comparison between all ALS patients and healthy control...
International audienceBackground: Studies showed the impact of sex and onset site (spinal or bulbar)...
<p>N = Number of subjects, Ln = natural log transform. EES score: 1 = defined as possible ALS, 2 = p...
We investigated whether the C9orf72 repeat expansion is associated with specific clinical features, ...
<p>Principal Component Analysis score plot for ALS (n = 50) and non ALS patients (n = 44).</p
Replicable risk factors for ALS include increasing age, family history and being male. The male: fem...
<p>Leukocyte phenotypes from HVs and ALS patients sub-grouped into Profiles 1 and 2 were compared. <...
In the past decade, increasingly large-scale genome wide association studies (GWAS) have gleaned ins...
<p>M: male; F: Female. B: bulbar onset; L: limb onset; MFO: interval from the observation of initial...
<p>Abbreviations: PMA = progressive muscular atrophy, ALS = amyotrophic lateral sclerosis, N = numbe...
<p>Box and dot plots show CSF NfH<sup>SMI35</sup> in ALS, Parkinson's disease (PD), and controls (CT...